Current and future antiviral drug therapies of hepatitis B chronic infection (Q28084820)

language of work or name

1 reference

18 May 2015

1 reference

World Journal of Hepatology

published in

1 reference

volume

7

1 reference

issue

8

1 reference

page(s)

1030-40

1 reference

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Telbivudine versus lamivudine in patients with chronic hepatitis B

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Emerging antivirals for the treatment of hepatitis B.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Chronic hepatitis B virus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Are novel combination therapies needed for chronic hepatitis B?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Antiviral therapies: focus on hepatitis B reverse transcriptase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

New perspectives in the therapy of chronic hepatitis B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Management of treatment failure in chronic hepatitis B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B infection: current concepts and future challenges.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

HBV life cycle and novel drug targets

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Current status of antiviral therapy for hepatitis B

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B virus replication induces methylation of both host and viral DNA.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Control of cccDNA function in hepatitis B virus infection.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Bayesian estimates of the evolutionary rate and age of hepatitis B virus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Viral recognition by Toll-like receptors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Cellular and virological mechanisms of HBV drug resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Diagnosis and management of pre-core mutant chronic hepatitis B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Viral dynamics in hepatitis B virus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Hepatitis B Virus Infection

2 June 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

[Hepatitis B virus genetic diversity and mutant].

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alfa.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

NK cells: a double-edged sword in chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Role of Toll-like receptor 2 in the immune response against hepadnaviral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I8.1030

A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4450180

Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials

27 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/26052392

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26052392

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/26052392

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4254/WJH.V7.I8.1030

1 reference

2130285

2130285

1 reference

1 reference

1 reference